DENTSPLY SIRONA Inc. (XRAY) Q3 2024 Earnings Call Transcript Summary
DENTSPLY SIRONA Inc. (XRAY) Q3 2024 Earnings Call Transcript Summary
Operating cash flow of $141 million was up 5% compared to the prior year due to improved inventory management.The following is a summary of the DENTSPLY SIRONA Inc. (XRAY) Q3 2024 Earnings Call Transcript:
以下是登士柏公司（XRAY）2024年第三季度業績會實錄摘要:
Financial Performance:
財務表現：
DENTSPLY SIRONA reported Q3 2024 revenue of $951 million, with organic sales up 1.3%.
Adjusted EPS for Q3 2024 was $0.50, up 3% from the prior year.
Operating cash flow of $141 million was up 5% compared to the prior year due to improved inventory management.
登士柏報告2024年第三季度營業收入爲95100萬美元，有機銷售增長1.3%。
2024年第三季度調整後每股收益爲0.50美元，比去年同期增長3%。
與去年相比，14100萬美元的營業活動現金流增長了5%，這是由於庫存管理得到改善。
Business Progress:
業務進展：
Significant focus on digital dentistry advancements, including the launch of Primescan 2.
Executed the majority of Phase 2 transformation activities, targeting full run rate savings by end of 2025.
Advanced ERP deployment including the first U.S. rollout, contributing to operational efficiency.
Over 85 new software updates delivered for DS Core, indicating robust development agility.
重點關注數字化牙科技術的進展，包括推出Primescan 2。
執行了大部分第2階段轉型活動，目標是到2025年底實現全部運行費用的節省。
愛文思控股首次在美國推出的高級ERP部署，有助於提高運營效率。
爲DS Core提供超過85個新軟件更新，顯示出強大的開發敏捷性。
Opportunities:
機會：
Continued growth in the digital dentistry space with the rollout of Primescan 2 and enhancements in DS Core.
The clinical education events like DS World, which have historically exceeded sales projections, are potential areas for further growth.
數字牙科領域持續增長，推出Primescan 2並改進DS Core。
像DS World這樣的臨床教育活動歷史上超過銷售預測，可能是進一步增長的潛在領域。
Risks:
風險：
Byte business suspension and ongoing regulatory review could impact future operations and market presence.
Global pressures on demand for implants and variable economic conditions continue to challenge the U.S. equipment market.
Byte業務暫停和持續的監管審查可能影響未來運營和市場影響力。
全球對種植牙需求和變化的經濟情況持續挑戰美國設備市場。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
